$12.11
-0.07 (-0.57%)
Open$11.82
Previous Close$12.18
Day High$12.44
Day Low$11.72
52W High$16.93
52W Low$8.48
Volume—
Avg Volume18.3K
Market Cap62.77M
P/E Ratio—
EPS$-2.40
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+64.9% upside
Current
$12.11
$12.11
Target
$19.97
$19.97
$17.96
$19.97 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.10M | 46.49M | 39.49M |
| Net Income | 3.70M | 3.34M | 2.56M |
| Profit Margin | 8.2% | 7.2% | 6.5% |
| EBITDA | 5.80M | 5.78M | 5.15M |
| Free Cash Flow | 3.02M | 2.12M | 2.20M |
| Rev Growth | +4.3% | +20.2% | +6.0% |
| Debt/Equity | 0.88 | 1.05 | 1.14 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |